PDC Energy (PDCE) was downgraded at Stifel Nicolaus to hold from buy. Company cut its production data, Stifel said. Stock also cut from the Select List.
Patterson (PDCO) was upgraded at UBS to buy from neutral. As a North American pure-play, the company will benefit most from increasing demand in the region, UBS said. Price target is $43.
Sarepta (SRPT) was initiated with a buy rating at Deutsche Bank. $45 price target. Muscular dystrophy can drive growth over the next several quarters, Deutsche said.
Stifel Nicolaus (SF) was downgraded to hold at TheStreet Ratings.Unum Group (UNM) was downgraded at Bank of America/Merrill Lynch to neutral from buy. $29 price target. Best-performing life insurer year to date, BofA/Merrill said.
STOCK COMMENTS/EPS CHANGESCitigroup (C) price target was raised at Deutsche Bank. Shares are now seen reaching $53. Company can continue to exceed sales expectations and move to $6 a share of earnings in 2015, Citi said. Buy rating. lululemon athletica (LULU) price target and estimates were reduced at UBS. Earnings estimates were cut after the company had to recall its Luon pants due to quality issues, said UBS. New price target is $77. Nike (NKE) estimates were reduced at UBS due to foreign exchange rates. The company reports earnings on Thursday. Norfolk Southern (NSC) price target and estimates were increased at Cowen. Intermodal and crude oil are driving better-than-expected traffic and operational metrics, Cowen said. Price target is $85. Onyx Pharmaceuticals (ONXX) price target and estimates were increased after a front-line Kyprolis survey showed robust uptake, said Jefferies. Price target is now $104. Proactive Life (PL) price target was increased at UBS to $39. Solid BVPS growth will drive stock upside, UBS said. Toronto-Dominion Bank (TD) was downgraded to hold at TheStreet Ratings. Vertex Pharmaceuticals (VRTX) price target and estimates were increased at J.P. Morgan. Changes made after speaking with physicians about the cystic fibrosis trial that is set to launch, said J.P. Morgan. Price target is now $86. Valeant (VRX) estimates were increased at UBS. Aggressive M&A is expected after meeting with management, UBS said. >To submit a news tip, email: firstname.lastname@example.org.
Follow TheStreet on Twitter and become a fan on Facebook.